arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

TransMedics Group, Inc.

TMDX
$86.98 ▼ -1.11 (-1.26%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
35 Visible periods
33 Metrics
Peer-ranked Benchmarks
Price Chart
83
Health
Excellent
Bullish
auto_awesome

Analytical Summary

TransMedics Group, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $3.0B
Dividend Yield
Revenue Growth 20.7%
Op. Margin 12.5%
ROIC 3.5%
FCF / Share $0.30
Trailing P/E 207.1x
Price / Book 5.8x
FCF Yield 0.3%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$189.95M
↑ +20.7%
Net Income Profit after all expenses
$7.32M
↓ -71.5%
Operating Margin Operating profit as % of sales
12.5%
↑ +63.5% 72th
FCF / Share Free cash flow per share
$0.30
↑ +183.8%
Long-Term Debt Long-term obligations
$58.80M
— +0.4%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
83
Returns
96
Financial Health
83
Cash Quality
49

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 35 quarters